In particular, for patients with resected NSCLC harboring EGFR mutations, given the role of EGFR-TKIs in advanced EGFR-mutant NSCLC, many clinical trials have been conducted to investigate the efficacy of EGFR-TKIs in the adjuvant setting [45–50]. Here, EGFR is linked to non-small cell lung carcinoma.